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Monoamine oxidase (MAO) catalyzes the oxidative de-
amination of a number of biogenic amines, including the
key neurotransmitters serotonin (5-HT), norepinephrine
(NE), and dopamine (DA) and the neuromodulator
phenylethylamine (PEA). Two forms of MAO, desig-
nated “MAO A” and “MAO B,” have been identified
on the basis of biochemical properties and, subsequently,
by cloning the relevant genes. Of the two, MAO A ex-
hibits a higher affinity for 5-HT and NE and for the
inhibitor clorgyline (Johnston 1968), whereas MAO B
has a higher affinity for PEA, benzylamine, and the in-
hibitor deprenyl (Knoll and Magyar 1972). DA is a sub-
strate for both MAO A and MAO B. Although most
tissues express both isoenzymes, human placenta and
fibroblasts express predominantly MAO A, and platelets
and lymphocytes express only MAO B (for review, see
Shih et al. 1999).
The ability of the MAOs to catabolize neurotrans-
mitters has made these enzymes attractive candidates in
the study of neurological diseases and psychiatric and
behavioral traits. Indeed, even before the genes for MAO
A and B were cloned, the role of MAO B in psychiatric
disorders was widely studied. Platelets, which are easily
obtained and lack MAO A expression, were the cell type
of choice for much of this work. Low platelet MAO B
activity has been associated with bipolar disorder, sui-
cidal behavior, and alcoholism (Devor et al. 1993), as
well as with sensation seeking and poor impulse control
(Oreland 1993; Holschneider and Shih 1998). However,
much of this biochemical work may need to be revisited,
given the recent finding that smoking inhibits both MAO
A activity and MAO B activity (Fowler et al. 1996a,
1996b). For instance, after correcting for the effect of
smoking, Simpson et al. (1999) determined that MAO
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B activity is not significantly reduced in schizophrenics.
With the successful cloning of human liver MAO A and
B, Bach et al. (1988) demonstrated that MAO A and B
are distinct, but closely related, X-linked genes (Shih
1991). The MAO A and MAO B genomic sequences
(Grimsby et al. 1991; Chen et al. 1992) and promoters
(Zhu et al. 1992; Zhu and Shih 1997) have been studied
extensively in the pursuit of polymorphisms that might
show these genes to be associated with psychiatric dis-
orders and behaviors. Perhaps the most intriguing find-
ing to emerge to date implicates MAO A in the control
of aggressive behavior in humans, a finding that we and
our collaborators have pursued in a knockout-mouse
model.
Deletion of MAOA and MAOB in Norrie disease
The gene for Norrie disease (ND) and the genes
MAOA and MAOB are arranged in tandem on human
Xp11.2-11.4 (Chen et al. 1995). Deletion ofND is some-
times accompanied by deletion of one or both of the
MAO genes and causes congenital blindness due to the
disrupted development and degeneration of the neuro-
retina (Berger et al. 1992). More than one-third of ND
patients also develop progressive hearing loss and man-
ifest mental retardation or psychoses (Sims et al. 1989).
Two such patients, studied in detail by Sims et al. (1989)
and Lenders et al. (1996), lack detectable MAO B ac-
tivity in their platelets and do not express MAO A
mRNA in their fibroblasts, and they show elevated
plasma and urine levels of NE, DA, 5-HT, and PEA.
Two brothers with a contiguous-gene deletion encom-
passing ND and MAO B show an increase in urinary
PEA levels, but their levels of 5-HT, NE, and DA are
normal (Lenders et al. 1996). These neurochemical
changes are consistent with the findings in Maoa-knock-
out (Cases et al. 1995) and Maob-knockout (Grimsby
et al. 1997) mice.
The clearest genetic evidence that the MAOs regulate
human behavior comes from the work of Brunner et al.
(1993a, 1993b), who studied a Dutch family in which
eight males manifest a complex behavioral syndrome
that includes borderline mental retardation and impul-
sive aggression. Sequencing of the MAOA gene showed,
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Table 1
Polymorphisms of the MAO A Gene which May Be Associated with Psychiatric Disorders and Behaviors
Polymorphism Disorder/Behavior Association Reference(s)
23-bp VNTR in intron 1 Tourette syndrome and drug abuse Yes Gade et al. (1998)
Bipolar disorder No Craddock et al. (1995); Lim et al. (1995); Mura-
matsu et al. (1997)
(GT)n repeat in intron 2 Bipolar disorder Yes Lim et al. (1995)
Bipolar disorder No Craddock et al. (1995); Muramatsu et al. (1997);
Parsian and Todd (1997)
Alcoholism Yes Parsian et al. (1995); Vanyukov et al. (1995);
Hsu et al. (1996)
Aggression No Vanyukov et al. (1995)
CrT mutation in exon 8 Aggression Yes Brunner et al. (1993a)
Fnu4HI-RFLP in exon 8 Bipolar disorder No Craddock et al. (1995); Lim et al. (1995); Mura-
matsu et al. (1997)
Alcoholism No Hsu et al. (1996)
EcoRV polymorphism in exon 14 Obsessive-compulsive disorder Yes Camarena et al. (1998)
Antisocial personality disorder No Lu et al. (1999)
Schizophrenia No Coron et al. (1996)
VNTR in the promoter Panic disorder Yes Deckert et al. (1999)
Antisocial personality disorder No Lu et al. (1999)
at position 936, a CrT mutation that introduces a pre-
mature-termination codon and that creates a null allele
in the gene. Urine samples from these affected males
showed decreased levels of 5-hydroxyindolecetic acid,
homovanillic acid, and 3-methoxy-4-hydroxyphenyl-
ethyleneglycol (Brunner et al. 1993a, 1993b), which are
the degradation products of 5-HT, DA, and NE, re-
spectively. Further studies are required to establish the
frequency of this mutation in humans, but urine analysis
of 119 inmates from a prison in Taiwan showed no
evidence for altered monoamine metabolism, suggesting
MAO A deficiency (H. M. Hwang and J. C. Shih, un-
published data). The aggressive behavior seen in men
lacking MAO A may, however, be unrelated to this ge-
netic defect; environmental substances, stress, drugs, or,
perhaps, other genetic factors in this family may increase
the susceptibility of these men to aggression. However,
as discussed below, the relationship between MAO A
deficiency and aggression has also been confirmed in
studies of MAO A–deficient mice.
Behavioral Phenotypes and MAO-Gene
Polymorphisms
The MAOA and MAOB sequences have been scru-
tinized for the existence of polymorphisms that might
be associated with other psychiatric phenotypes. Table
1 describes the MAOA polymorphisms that have been
reported to be associated with such behavioral pheno-
types as aggression and substance abuse (see Reich et al.
1999 [in this issue]), as well as affective disorders, such
as bipolar and panic disorder. As is common in such
studies (see O’Donovan and Owens 1999 [in this issue]),
associations with these phenotypes prove difficult to rep-
licate, and both confirmatory and negative findings are
presented in the table. Polymorphisms in the MAOB
gene have also been identified, but no behavioral or psy-
chiatric phenotypes have yet been associated with these
variants. Most of the known MAOA polymorphisms
either affect intronic sequences or introduce a silent
change in the open-reading-frame polymorphisms (i.e.,
the EcoRV and Fnu4HI polymorphisms); these variants
are unlikely to affect MAO function, although they may
be in disequilibrium with other, as yet unidentified, func-
tional variants. Recently, however, a VNTR polymor-
phism that affects transcriptional activity has been found
in the MAOA-gene promoter (Zhu et al. 1992, 1994;
Sabol et al. 1998). This variant, which is associated with
lower levels of MAO A activity, occurs with a higher-
than-normal frequency in patients with panic disorder
(Deckert et al. 1999) but never occurs in patients with
antisocial personality disorder (Lu et al. 1999).
Behavioral and Metabolic Features of
MAO A–Deficient Mice
To test the role of MAO A in behavior in a system
that permits experimental manipulation, we established
a line of mice with a targeted disruption of the Maoa
gene (Cases et al. 1995). We observed that males in this
strain exhibit a significant increase in brain levels of 5-
HT and NE and a modest increase in DA, confirming
that the substrate specificities of the mouse MAOs are
similar to those in humans. Crucially, these males man-
ifest enhanced aggression, as assessed by observation of
confrontations between intruder and resident mice under
standardized conditions (Cases et al. 1995; Shih et al.
1999).
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Figure 1 Effect of ketanserin and TBZ on aggressive behavior
of MAO A–deficient mice in resident-intruder confrontations. The du-
ration of aggressive behavior of the more aggressive mouse in each
pair is expressed in seconds (s) during the first 10 min after the first
attack. he number of mouse pairs in each condition. Multiwayn = t
comparisons are by one-way ANOVA and the Tukey-Kramer test for
control versus drug-treated mice. A single asterisk (*) denotes P !
, and double asterisks (**) denote . Data are from Shih et.05 P ! .01
al. (in press).
Drug studies lend further support to the notion that
high CNS levels of monoamine neurotransmitters pro-
mote aggressive behavior. Ketanserin and tetrabenazine
(TBZ) both act as antagonists of the vesicular mono-
amine transporter VMAT2 (Leysen et al. 1988; Roth et
al. 1987), and ketanserin also interferes with 5-HT, by
blocking 5-HT2A receptors. As shown in figure 1, both
of these drugs diminish the aggressive behavior of MAO
A–deficient mice in a dose-dependent manner (Shih et
al., in press). These drugs also inhibit the behavior of
wild-type mice, but the aggression is much lower in the
wild-type animals when compared with the Maoa-
knockout mice. Thus, untreated wild-type males exhibit
aggressive behavior for 48.7  18.0 s during the first
10 min after a resident and an intruder animal begin to
fight; with mice of the Maoa-knockout genotype, the
aggression occurs for 93.2 28.9 s. The antiaggressive
effect of TBZ and at least part of the effect of ketanserin
may be mediated by their effects on VMAT2.
MAO A–deficient mice also show more efficient emo-
tional learning than do wild-type animals, by several
measures, including the freezing-response-after-foot-
shock training (Kim et al. 1997). Evidently, fear-condi-
tioned learning is enhanced in these mice as a result of
their elevated monoamine levels. This learning pheno-
type is consistent both with earlier pharmacological
studies, which showed that the injection of monoamines
into the brains of mice increases fear-memory learning,
and with subsequent work with drugs that lower the
levels of monoamines, which are found to interfere with
this type of learning.
Structural and Developmental Changes in MAO
A–Deficient Brains in Mice
In addition to these behavioral differences between
Maoa-knockout and wild-type mice, the phenotype of
the knockout animals includes some subtle changes in
neuronal structure and patterns of gene expression in
the brain. The absence of MAO A activity affects the
distribution throughout development of 5-HT and of
factors that interact with it. Immunolabeling experi-
ments show that 5-HT accumulates transiently at nu-
merous atypical locations during the embryonic and
postnatal development of Maoa-knockout mice, includ-
ing sites within the telencephalon, the diencephalon, and
the brain stem (Cases et al. 1998). Interestingly, catech-
olaminergic cells at diverse sites, which would not be
expected to express 5-HT, also display transient 5-HT
immunoreactivity, perhaps as a result of 5-HT uptake
via the DA or NE plasma-membrane transporter. It ap-
pears that neuron populations that form highly precise
projection maps could be affected by excess 5-HT during
development (Cases et al. 1998), and, indeed, the in-
creased 5-HT levels in brains from Maoa-knockout pups
causes cytoarchitectural alterations in the somatosensory
cortex. As Cases et al. (1996, 1998) have shown, these
changes in brain structure may be related to the en-
hanced aggression of MAO A–deficient mice, because
administration of p-chlorophenylalanine—which inhib-
its tryptophan hydroxylase, the rate-limiting enzyme in
5-HT biosynthesis—reverses both the structural changes
and the aggressive behavior of adults (Cases et al. 1996).
Further clues to the brain structures involved in aggres-
sion come from the work of Shi et al. (1998), who used
a tissue-specific promoter to restore MAOA expression
specifically to the forebrain of Maoa-knockout animals.
The duration of aggressive behavior is reduced to normal
levels in these transgenic mice, suggesting that the lack
of MAO A in the forebrain of Maoa-knockout mice
underlies their enhanced aggression.
Radio-ligand binding and autoradiography have also
shown that the numbers of sites that are positive for
VMAT2, 5-HT1A, 5-HT2A, or 5-HT2C are decreased in
brains of MAO A–deficient mice (Shih et al. in press),
perhaps because the excess ligand causes these factors
to be down-regulated. Interestingly, however, MAO B
does not appear to be altered in its expression level in
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Maoa-knockout mice. The apparent absence of com-
pensatory changes in expression may make these mutant
animals valuable tools to study the distribution and
function of MAO B. Brains of Maoa-knockout pups ac-
cumulate 5-HT at a concentration nine times higher than
do wild-type mice at the same stage (Cases et al. 1995),
but in adult animals the difference is only twofold. This
change probably indicates that MAO B is capable of
oxidation of 5-HT in vivo in the absence of MAO A,
and its timing may reflect the late expression of MAO
B. Thus, it is reasonable to speculate that 5-HT would
be greatly enhanced in mice deficient for both MAO
genes. We are currently generating Maoa/Maob–double-
knockout mice, which may recapitulate some of the fea-
tures of the patients with ND that have been discussed
above. The development of mice lacking both MAO A
and MAO B should allow us to explore the genetic in-
teractions between Maoa and Maob in both neural de-
velopment and the control of behavior.
Grimsby et al. (1997) showed that the brain level of
PEA is eightfold higher in Maob-knockout mice than in
wild types, although 5-HT, NE, and DA levels are not
altered. The effect of MAO B on PEA is consistent with
findings in patients with ND who lack MAO B expres-
sion (Lenders et al. 1996) and with suggestions that this
neurotransmitter may modulate mood and affect (Lin-
noila et al. 1983).
Concluding Remarks
The role of MAO A in aggression, first identified by
Brunner et al. (1993a, 1993b), has been confirmed in
MAO A–deficient mice, which, like the men in the Dutch
family, show increased brain levels of 5-HT, NE, and
DA and manifest enhanced aggression. However, ag-
gression is a complicated behavior, and mice that lack
any of several genes also manifest altered aggression,
including those for the adenosine 2a receptor (Ledent et
al. 1997), estrogen receptor (Ogawa et al. 1996), 5-HT1B
receptor (Ramboz et al. 1996), bcr (a GTPase-activating
protein for Rac [Voncken et al. 1998]), CaMKIIa (May-
ford et al. 1996), catechol-o-methyltransferase (Gogos
et al. 1998), nitric oxide synthase (Kriegsfeld et al.
1997), and oxytocin (DeVries et al. 1997). To date, no
lesions in these genes in humans have been reported, and
these mouse data have yet to be applied to the treatment
of behavioral or psychiatric disorders. Most of the drugs
now used to treat aggressive behavior act on brain DA,
5-HT, and a-aminobutyric acid-receptor subtypes (Mi-
czek et al. 1994). However, these medications, including
benzodiazepines and antipsychotics, treat aggression
largely by sedating the patient. Doses of ketanserin and
TBZ, which abolish the aggressive behavior of MAO
A–deficient mice, on the other hand, do not produce
sedation (Shih et al., in press). Therefore, ketanserin and
TBZ may be developed as novel antiaggressive agents.
Further studies using Maoa- and Maob-knockout mice
will provide new insights into human neuropsychiatric
disorders. New techniques, such as cDNA expression
arrays, may help to detect new genes and polymorphisms
that are associated with neuropsychiatric disorders and
behaviors.
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